UPDATE: Baird Upgrades Arrowhead Research (ARWR) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
SVB Leerink Downgrades The Medicines Company (MDCO) to Market Perform
November 25, 2019 8:10 PM ESTSVB Leerink analyst Joseph Schwartz downgraded The Medicines Company (NASDAQ: MDCO) from Outperform to Market Perform with a price target of $85.00 (from $78.00).
For an analyst ratings summary and ratings history on The Medicines Company... More
